Multiple myeloma physicians and researchers are gathering at the 16^th Congress of the European Hematology Association (EHA) in London to share the latest findings in the field.  The meeting started on Thursday and will run through tomorrow.

The Myeloma Beacon will report on the most important new findings related to multiple myeloma over the next couple of weeks.

The research presented at the meeting will cover all areas of hematology, which is the study of blood, blood-forming organs, and blood-related …

Results of a Phase 2 clin­i­cal trial show that elotuzumab in com­bi­na­tion with Revlimid and low-dose dexa­meth­a­sone is safe and ef­fec­tive in re­lapsed / refractory mul­ti­ple myeloma patients.

“Elotuzumab in com­bi­na­tion with Revlimid and low-dose dexa­meth­a­sone has a very high re­sponse rate,” said Dr. Philippe Moreau from the Uni­ver­sity Hospital in Nantes, France, when he pre­sented the findings at the 47^th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Sunday.

“[The com­bi­na­tion] seems to be superior to Revlimid …

While I was in Chicago for the American Society of Clinical Oncology (ASCO) meeting this past weekend, I noticed a renewed emphasis by clinicians and researchers to aggressively move forward with individual, targeted cancer therapies.

Attempts to use patient-specific antibodies as a way to deliver innovative anti-cancer therapies grabbed the headlines.

But there is a far simpler way to use patient-specific information. Tailoring dosing to each individual can get the optimum results with minimal side effects, using anti-cancer drugs and …

Results of a Phase 1 clinical trial suggest that the investigational drug LY2127399 in combination with Velcade is safe and effective enough to deserve further study as a potential treatment for multiple myeloma.

“We are very encouraged by these results and would like to move this forward to a randomized trial comparing LY2127399 and Velcade with Velcade alone,” said Dr. Noopur Raje, from Dana-Farber Cancer Institute when she presented these findings at the 47^th Annual Meeting of the American Society …

Monday was the fourth day of the American Society of Clinical Oncology (ASCO 2011) annual meeting in Chicago.  Although the meeting concluded yes­ter­day, Monday was the last day of the meeting that con­tained any myeloma-relevant ma­teri­al.

The morn­ing started with a session recapping highlights of the meeting from Sunday.  Dr. Ivan Borello from the Johns Hopkins Uni­ver­sity School of Medicine was invited to give a 15-minute pre­sen­ta­tion recapping the myeloma highlights (see Part 1 and Part 2 of …

I have always been fascinated and inspired by stories of courage through adversity. In that vein, an event took place during a week in late May that gave me great pause to reflect upon how I deal with the reality of living with multiple myeloma.

On May 22, a monstrous tornado, 3/4 of a mile wide, 13.8 miles long, and packing winds in excess of 200 miles per hour, descended upon Joplin, Missouri, a town just an hour to the …

This past Sunday was the third day of the American Society of Clinical Oncology (ASCO) 2011 annual meeting, and it was a particularly busy day for meeting attendees interested in multiple myeloma.

The Beacon published an update yesterday covering two sets of presentations made at Sunday’s oral session about multiple myeloma.  This article covers the other set of presentations, which was about myeloma bone disease, as well as material …